KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.48
-0.02 (-3.85%)
Financial Highlights (FY 2026)
Revenue
426.2K
Net Income
-423,372,815
Gross Margin
-14.6%
Profit Margin
-14,394.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -14.6% | 49.0% | 49.0% | 49.0% |
| Operating Margin | -29,850.3% | 21.0% | 20.9% | 20.0% |
| Profit Margin | -14,394.0% | 12.0% | 16.2% | 12.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 426.2K | 3.90M | 3.72M | 4.29M |
| Gross Profit | -62,097 | 1.91M | 1.82M | 2.10M |
| Operating Income | -127,223,001 | 818.7K | 777.4K | 858.1K |
| Net Income | -423,372,815 | 467.4K | 601.6K | 528.1K |
| Gross Margin | -14.6% | 49.0% | 49.0% | 49.0% |
| Operating Margin | -29,850.3% | 21.0% | 20.9% | 20.0% |
| Profit Margin | -14,394.0% | 12.0% | 16.2% | 12.3% |
| Rev Growth | — | +18.2% | +4.0% | +10.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 6.27M | 6.55M | 6.27M |
| Total Equity | — | 7.03M | 8.06M | 8.15M |
| D/E Ratio | — | 0.89 | 0.81 | 0.77 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -423,356,547 | 1.16M | 1.10M | 1.24M |
| Free Cash Flow | — | 801.3K | 617.9K | 781.1K |